Total protein was extracted with RIPA buffer (Pierce, no. 89900) supplemented with
protease inhibitor (Life Technologies, no. 1861280) and quantified using the
BCA Protein Assay (ThermoFisher Scientific). Proteins were separated on
Bolt 4-12% Bis-Tris Plus gels (Life Technologies, no. NW04120) and transferred to polyvinylidene difluoride membranes. Membranes were probed with antibodies against GCLC (Proteintech, no. 12601-1-AP, 1:2000 dilution), HuR (Santa Cruz Biotechnology, no. SC-5261, clone 3A2, 1:2000 dilution)
21 (link),55 (link)–60 (link),
Lamin A/C (Cell Signaling, no. 4777, 1:2000 dilution),
α-Tubulin (Proteintech, no. 11224-1-AP, 1:4000 dilution), and
β-Actin (Santa Cruz Biotechnology, no. SC-47778, 1:4000 dilution). Blots were probed with secondary antibodies customized for the Odyssey Imaging system Secondary antibodies (
680RD Goat anti-Mouse IgG (Li-COR, no. 926-68070, 1:20000 dilution) and
800CW Goat anti-Rabbit IgG (Li-COR, no. 926-32211, 1:10000 dilution). The density of blots was quantified using Image Studio Software v.5.2.5.
Vaziri-Gohar A., Hue J.J., Abbas A., Graor H.J., Hajihassani O., Zarei M., Titomihelakis G., Feczko J., Rathore M., Chelstowska S., Loftus A.W., Wang R., Zarei M., Goudarzi M., Zhang R., Willard B., Zhang L., Kresak A., Willis J.E., Wang G.M., Tatsuoka C., Salvino J.M., Bederman I., Brunengraber H., Lyssiotis C.A., Brody J.R, & Winter J.M. (2023). Increased glucose availability sensitizes pancreatic cancer to chemotherapy. Nature Communications, 14, 3823.